VISCHER assists AstraZeneca as investor in a USD 80 m financing round of ADC Therapeutics Sàrl, Epalinges, an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. ADC Therapeutics intends to use this financing to progress ADC Therapeutics’ product portfolio, including ADCT-301 for lymphoma and leukemia now in Phase I and a collaboration to develop up to two ADCs for commercialisation with MedImmune, the global biologics research and development arm of AstraZeneca.

Covington & Burling LLP and VISCHER AG advise AstraZeneca in this financing. The team at VISCHER includes Christian Wyss and Stefan Grieder.